BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Korea's Samsung Biologics buys PolyPeptide for CHF 1.46 B

July 20, 2026 | News

Samsung Biologics will bring together PolyPeptide's highly experienced team and specialised peptide expertise



South Korea-based Samsung Biologics has announced the launch of an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group AG, a leading global contract development and manufacturing organisation (CDMO) specialising in peptide-based active pharmaceutical ingredients (APIs).

Under the terms of the offer, PolyPeptide shareholders will receive CHF 44.31 in cash for each PolyPeptide share, representing an implied equity value of approximately CHF 1.46 billion.

With this transaction, Samsung Biologics will expand its capabilities beyond antibodies and ADCs to include peptide therapeutics, one of the fastest-growing segments of the biopharmaceutical industry, driven by surging global demand for obesity treatments and the continued expansion of peptide-based therapies into new disease areas.

The transaction brings together Samsung Biologics' global manufacturing scale with PolyPeptide's specialised peptide expertise to create a differentiated, end-to-end multi-modality CDMO platform. PolyPeptide stands as one of the industry's top peptide CDMOs, distinguished by its advanced technology platform and proven track record, with more than 70 years of API manufacturing heritage and over 1,000 therapeutic peptides produced to date.

Samsung Biologics aims to serve clients across a broader range of therapeutic modalities by addressing growing demand for peptide-based therapeutics, particularly in obesity and diabetes, including GLP-1 therapies, while advancing innovation across high-growth areas such as oncology and other emerging indications.

The planned acquisition extends beyond adding capacity; it lays the foundation for Samsung Biologics' next phase of growth, supported by a strong pipeline of active peptide projects that includes a deep late-stage portfolio. PolyPeptide operates global sites across Sweden, Belgium, France, the United States, India, together with a corporate office in Switzerland and a separate Innovation Center in Strasbourg, France, with capabilities encompassing R&D, development, and commercial manufacturing.